Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

<jats:title>ABSTRACT</jats:title><jats:p>In a recent vaccine trial performed with African children, immunization with a recombinant protein based on<jats:named-content content-type="genus-species">Plasmodium falciparum</jats:named-content>apical membrane antigen 1 (AMA-1) conferred a significant degree of strain-specific resistance against malaria. To contribute to the efforts of generating a vaccine against<jats:named-content content-type="genus-species">Plasmodium vivax</jats:named-content>malaria, we expressed the ectodomain of<jats:named-content content-type="genus-species">P. vivax</jats:named-content>AMA-1 (PvAMA-1) as a secreted soluble protein in the methylotrophic yeast<jats:named-content content-type="genus-species">Pichia pastoris</jats:named-content>. Recognized by a high percentage of sera from individuals infected by<jats:named-content content-type="genus-species">P. vivax</jats:named-content>, this recombinant protein was found to have maintained its antigenicity. The immunogenicity of this protein was evaluated in mice using immunization protocols that included homologous and heterologous prime-boost strategies with plasmid DNA and recombinant protein. We used the following formulations containing different adjuvants: aluminum salts (Alum),<jats:named-content content-type="genus-species">Bordetella pertussis</jats:named-content>monophosphoryl lipid A (MPLA), flagellin FliC from<jats:named-content content-type="genus-species">Salmonella enterica</jats:named-content>serovar Typhimurium, saponin Quil A, or incomplete Freund's adjuvant (IFA). The formulations containing the adjuvants Quil A or IFA elicited the highest IgG antibody titers. Significant antibody titers were also obtained using a formulation developed for human use containing MPLA or Alum plus MPLA. Recombinant PvAMA-1 produced under “conditions of good laboratory practice” provided a good yield, high purity, low endotoxin levels, and no microbial contaminants and reproduced the experimental immunizations. Most relevant for vaccine development was the fact that immunization with PvAMA-1 elicited invasion-inhibitory antibodies against different Asian isolates of<jats:named-content content-type="genus-species">P. vivax</jats:named-content>. Our results show that AMA-1 expressed in<jats:named-content content-type="genus-species">P. pastoris</jats:named-content>is a promising antigen for use in future preclinical and clinical studies.</jats:p>

Original publication

DOI

10.1128/iai.01169-13

Type

Journal

Infection and Immunity

Publisher

American Society for Microbiology

Publication Date

03/2014

Volume

82

Pages

1296 - 1307